MedWatch

Jefferies fears renewed pressure on Novo Nordisk's growth

Financial analyst Jefferies predicts that Novo Nordisk will be subjected to heated price competition when the patent on obesity medication Victoza expires in a few years. Novo Nordisk does not agree with this risk assessment.

Photo: Novo Nordisk / PR

Five years ago, insulin prices were under such high pressure that Novo Nordisk had to downgrade its guidance multiple times, resulting in grave share price declines. The financial analyst Jefferies predicts Novo's growth engine with GLP-1 medication may encounter a similar type of pressure after 2023-24, when the patent for Novo Nordisk's first big seller in the GLP-1 series, Victoza, expires, according to Danish business daily Børsen.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

China approves Y-mabs drug

Y-mabs’ cancer treatment Danyelza, which is currently licensed to Sciclones, has been approved by the Chinese authorities. Y-mabs will receive double-digit sales royalties.

Further reading

Related articles

Latest news

See all jobs